Irinotecan
- TRADE NAMES: Camptosar (Pfizer); Onivyde (Merrimack)
- INDICATIONS: Metastatic colorectal carcinoma (Camptosar); metastatic adenocarcinoma of the pancreas (Onivyde - in combination with fluorouracil and leucovorin). Advanced pancreatic cancer in combination with oxaliplatin/fluorouracil/leucovorin (FOLFIRINOX or FOLFOXIRI). Used in combination with fluorouracil and leucovorin (FOLFIRI) for treatment of advanced-stage and metastatic colorectal cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Topoisomerase 1 inhibitor
- HALF-LIFE: 6–10 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Bevacizumab, Itraconazole, Ketoconazole, Lapatinib, Safinamide, Sorafenib, St John's Wort, Strong CYP3A4 inhibitors, Voriconazole
PREGNANCY CATEGORY: D
DIARRHEA and MYELOSUPPRESSION (Camptosar).
SEVERE NEUTROPENIA and SEVERE DIARRHEA (Onivyde)
See full prescribing information for complete boxed warnings.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 03/22/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric